In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist

PPAR Research

Volumn , Issue , 2012, Pages

  He, B K ^a,b   Ning, Z Q ^a   Li, Z B ^a   Shan, S ^a   Pan, D S ^a   Ko, B C B ^c   Li, P P ^d   Shen, Z F ^d   Dou, G F ^e   Zhang, B L ^f   Lu, X P ^a   Gao, Y ^b  

^a Shenzhen Hi Tech Industrial Park   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d INSTITUTE OF MATERIA MEDICA   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^f TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHIGLITAZAR; CHIGLITAZAR H 3; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RADIOISOTOPE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HEART; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIPID METABOLISM; LIVER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS; RAT; SKELETAL MUSCLE; THERMOGENESIS; TISSUE DISTRIBUTION; UPREGULATION;

EID: 84869038701     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/546548     Document Type: Article

References (45)

1. Quinn C. E., Hamilton P. K., Lockhart C. J., McVeigh G. E., Thiazolidinediones: effects on insulin resistance and the cardiovascular system. British Journal of Pharmacology 2008 153 4 636 645 2-s2.0-39449114610 10.1038/sj.bjp.0707452 (Pubitemid 351271751)
2. Semple R. K., Chatterjee V. K. K., O'Rahilly S., PPAR γ and human metabolic disease. Journal of Clinical Investigation 2006 116 3 581 589 2-s2.0-33644644599 10.1172/JCI28003 (Pubitemid 43326862)
3. Qatanani M., Lazar M. A., Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes and Development 2007 21 12 1443 1455 2-s2.0-34250773451 10.1101/gad.1550907 (Pubitemid 46955717)
4. Lefebvre P., Chinetti G., Fruchart J. C., Staels B., Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. Journal of Clinical Investigation 2006 116 3 571 580 2-s2.0-33644652183 10.1172/JCI27989 (Pubitemid 43326861)
5. Han S. H., Quon M. J., Koh K. K., Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005 46 5 1086 1092 2-s2.0-27444437661 10.1161/01.HYP.0000187900. 36455.4c (Pubitemid 41533006)
6. Barish G. D., Narkar V. A., Evans R. M., PPAR δ: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 2006 116 3 590 597 2-s2.0-33644645013 10.1172/JCI27955 (Pubitemid 43326863)
7. Wang Y. X., Lee C. H., Tiep S., Yu R. T., Ham J., Kang H., Evans R. M., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003 113 2 159 170 2-s2.0-0037453718 10.1016/S0092- 8674(03)00269-1 (Pubitemid 36514968)
8. Risérus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., Fang Z., Hegde P., Richards D., Sarov-Blat L., Strum J. C., Basu S., Cheeseman J., Fielding B. A., Humphreys S. M., Danoff T., Moore N. R., Murgatroyd P., O'Rahilly S., Sutton P., Willson T., Hassall D., Frayn K. N., Karpe F., Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008 57 2 332 339 2-s2.0-39649101196 10.2337/db07-1318
9. Bristol-Myers Squibb,. Advisory Committee briefing document: Pargluva (muraglitazar, BMS-298585). FDA Web site, 2005
10. Nissen S. E., Wolski K., Topol E. J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Journal of the American Medical Association 2005 294 20 2581 2586 2-s2.0-28144451163 10.1001/jama.294.20.joc50147 (Pubitemid 41697247)
11. Bristol-Meyer Squibb,. Bristol-Meyer Squibb Company News. BMY announces discontinuation of development of muraglitazar, an investigational oral treatment for Type 2 Diabetes, 2006
12. Nesto R. W., Bell D., Bonow R. O., Fonseca V., Grundy S. M., Horton E. S., Le Winter M., Porte D., Semenkovich C. F., Smith S., Young L. H., Kahn R., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004 27 1 256 263 2-s2.0-10744221639 10.2337/diacare.27.1.256 (Pubitemid 38196741)
13. Kahn S. E., Haffner S. M., Heise M. A., Herman W. H., Holman R. R., Jones N. P., Kravitz B. G., Lachin J. M., O'Neill M. C., Zinman B., Viberti G., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 2006 355 23 2427 2443 2-s2.0-33845405222 10.1056/NEJMoa066224 (Pubitemid 44903747)
14. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 2007 356 24 2457 2471 2-s2.0-34250212715 (Pubitemid 46919772)
15. Higgins L. S., Mantzoros C. S., The development of INT131 as a selective PPAR γ modulator: approach to a safer insulin sensitizer. PPAR Research 2008 2008 9 936906 10.1155/2008/936906
16. Choi J. H., Banks A. S., Estall J. L., Kajimura S., Boström P., Laznik D., Ruas J. L., Chalmers M. J., Kamenecka T. M., Blüher M., Griffin P. R., Spiegelman B. M., Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR γ 3 by Cdk5. Nature 2010 466 7305 451 456 2-s2.0-77954941113 10.1038/nature09291
17. Choi J. H., Banks A. S., Kamenecka T. M., Busby S. A., Chalmers M. J., Kumar N., Antidiabetic actions of a non-agonist PPAR γ ligand blocking Cdk5-mediated phosphorylation. Nature 2011 477 477 481
18. Li P. P., Shan S., Chen Y. T., Ning Z. Q., Sun S. J., Liu Q., Lu X. P., Xie M. Z., Shen Z. F., The PPAR α / γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. British Journal of Pharmacology 2006 148 5 610 618 2-s2.0-33745606757 10.1038/sj.bjp.0706745 (Pubitemid 43993051)
19. Pawliczak R., Han C., Huang X. L., Demetris A. J., Shelhamer J. H., Wu T., 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor γ activation in human lung epithelial cells. Journal of Biological Chemistry 2002 277 36 33153 33163 2-s2.0-0037031820 10.1074/jbc.M200246200 (Pubitemid 34984833)
20. Halpin R. A., Geer L. A., Zhang K. E., Marks T. M., Dean D. C., Allen N., Jones A., Melillo D., Doss G., Vyas K. P., The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metabolism and Disposition 2000 28 10 1244 1254 2-s2.0-0033815066
21. Sewter C., Berger D., Considine R. V., Medina G., Rochford J., Ciaraldi T., Henry R., Dohm L., Flier J. S., O'Rahilly S., Vidal-Puig A. J., Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor- α Diabetes 2002 51 4 1035 1041 2-s2.0-0036228456 (Pubitemid 34438347)
22. Oberfield J. L., Collins J. L., Holmes C. P., Goreham D. M., Cooper J. P., Cobb J. E., Lenhard J. M., Hull-Ryde E. A., Mohr C. P., Blanchard S. G., Parks D. J., Moore L. B., Lehmann J. M., Plunket K., Miller A. B., Milburn M. V., Kliewer S. A., Willson T. M., A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America 1999 96 11 6102 6106 2-s2.0-13044286786 10.1073/pnas.96.11.6102 (Pubitemid 29256626)
23. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., Rufer A., Ruf A., Kuhn B., Märki H. P., Mizrahi J., Sebokova E., Niesor E., Meyer M., A novel partial agonist of peroxisome proliferator-activated receptor- γ (PPAR γ) recruits PPAR γ -coactivator-1 α prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Molecular Endocrinology 2006 20 4 809 830 2-s2.0-33645394377 10.1210/me.2005-0171
24. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R. X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., Sakai J., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929 2-s2.0-9144271149 10.1073/pnas.0306981100 (Pubitemid 38021091)
25. Sprecher D. L., Massien C., Pearce G., Billin A. N., Perlstein I., Willson T. M., Hassall D. G., Ancellin N., Patterson S. D., Lobe D. C., Johnson T. G., Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 359 365 2-s2.0-33846443997 10.1161/01.ATV.0000252790.70572.0c (Pubitemid 46143052)
26. Bruning J. B., Chalmers M. J., Prasad S., Busby S. A., Kamenecka T. M., He Y., Nettles K. W., Griffin P. R., Partial agonists activate PPAR γ using a helix 12 independent mechanism. Structure 2007 15 10 1258 1271 2-s2.0-35148887302 10.1016/j.str.2007.07.014 (Pubitemid 47539157)
27. Houtkooper R. H., Auwerx J., Obesity: new life for antidiabetic drugs. Nature 2010 466 7305 443 444 2-s2.0-77954911499 10.1038/466443a
28. Gerrits C. M., Bhattacharya M., Manthena S., Baran R., Perez A., Kupfer S., A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiology and Drug Safety 2007 16 12 1314 1316 2-s2.0-37349100453 10.1002/pds.1497 (Pubitemid 350303445)
29. Goldberg R. B., Kendall D. M., Deeg M. A., Buse J. B., Zagar A. J., Pinaire J. A., Tan M. H., Khan M. A., Perez A. T., Jacober S. J., A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 7 1547 1554 2-s2.0-21544466158 10.2337/diacare.28.7.1547 (Pubitemid 40923063)
30. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). Journal of Biological Chemistry 1995 270 22 12953 12956 2-s2.0-0029016829 10.1074/jbc.270.22.12953
31. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., Sawada H., Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochemical and Biophysical Research Communications 2000 278 3 704 711 2-s2.0-0034735992 10.1006/bbrc.2000.3868
32. Schupp M., Janke J., Clasen R., Unger T., Kintscher U., Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γ activity. Circulation 2004 109 17 2054 2057 2-s2.0-2442451618 10.1161/01.CIR.0000127955.36250.65 (Pubitemid 38620211)
33. Qin S., Liu T., Kamanna V. S., Kashyap M. L., Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR- α Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 11 2428 2434 2-s2.0-36048957806 10.1161/ATVBAHA.107.150193 (Pubitemid 350203960)
34. Bogacka I., Xie H., Bray G. A., Smith S. R., Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005 54 5 1392 1399 2-s2.0-17844385363 10.2337/diabetes.54.5.1392 (Pubitemid 40586669)
35. Alvarez B., Carbó N., López-Soriano J., Drivdahl R. H., Busquets S., López-Soriano F. J., Argilés J. M., Quinn L. S., Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica et Biophysica Acta 2002 1570 1 33 37 2-s2.0-0037084989 10.1016/S0304-4165(02)00148- 4 (Pubitemid 34311891)
36. Almendro V., Busquets S., Ametller E., Carbó N., Figueras M., Fuster G., Argilés J. M., López-Soriano F. J., Effects of interleukin-15 on lipid oxidation. Disposal of an oral [14C]-triolein load. Biochimica et Biophysica Acta 2006 1761 1 37 42 2-s2.0-33646039349 10.1016/j.bbalip.2005.12.006
37. Almendro V., Fuster G., Busquets S., Ametller E., Figueras M., Argilés J. M., López-Soriano F. J., Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. Obesity 2008 16 2 285 289 2-s2.0-39449134021 10.1038/oby.2007.47 (Pubitemid 351271906)
38. Brennan A. M., Mantzoros C. S., Drug Insight: the role of leptin in human physiology and pathophysiologyemerging clinical applications. Nature Clinical Practice Endocrinology and Metabolism 2006 2 6 318 327 2-s2.0-33745106645 10.1038/ncpendmet0196 (Pubitemid 43885911)
39. Desvergne B., Michalik L., Wahli W., Transcriptional regulation of metabolism. Physiological Reviews 2006 86 2 465 514 2-s2.0-33645863768 10.1152/physrev.00025.2005
40. Ducluzeau P. H., Perretti N., Laville M., Andreelli F., Vega N., Riou J. P., Vidal H., Regulation by insulin of gene expression in human skeletal muscle and adipose tissue: evidence for specific defects in type 2 diabetes. Diabetes 2001 50 5 1134 1142 2-s2.0-0035029812 (Pubitemid 32374545)
41. Peraza M. A., Burdick A. D., Marin H. E., Gonzalez F. J., Peters J. M., The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicological Sciences 2006 90 2 269 295 2-s2.0-33645112691 10.1093/toxsci/kfj062
42. Guan Y., Hao C., Cha D. R., Rao R., Lu W., Kohan D. E., Magnuson M. A., Redha R., Zhang Y., Breyer M. D., Thiazolidinediones expand body fluid volume through PPAR γ stimulation of ENaC-mediated renal salt absorption. Nature Medicine 2005 11 8 861 866 2-s2.0-23844472901 10.1038/nm1278 (Pubitemid 41161118)
43. Zhang H., Zhang A., Kohan D. E., Nelson R. D., Gonzalez F. J., Yang T., Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proceedings of the National Academy of Sciences of the United States of America 2005 102 26 9406 9411 2-s2.0-21544479710 10.1073/pnas.0501744102 (Pubitemid 40923576)
44. GlaxoSmithKline,. AVANDIA Label. FDA Web site, 2008
45. Takeda,. ACTOS Label. FDA Web site, 2007